Skip to main content
Top
Published in: BMC Public Health 1/2019

Open Access 01-12-2019 | Human Immunodeficiency Virus | Research article

Predictors of loss to follow-up among children on long-term antiretroviral therapy in Zambia (2003–2015)

Authors: Jane N. Mutanga, Simon Mutembo, Amara E. Ezeamama, Xiao Song, Robert C. Fubisha, Kunda Mutesu-Kapembwa, Derrick Sialondwe, Brenda Simuchembu, Jelita Chinyonga, Philip E. Thuma, Christopher C. Whalen

Published in: BMC Public Health | Issue 1/2019

Login to get access

Abstract

Background

Retention in care is critical for children living with HIV taking antiretroviral therapy (ART). Loss to follow-up (LTFU) is high in HIV treatment programs in resource limited settings. We estimated the cumulative incidence of LTFU and identified associated risk factors among children on ART at Livingstone Central Hospital (LCH), Zambia.

Methods

Using a retrospective cohort study design, we abstracted data from medical records of children who received ART between 2003 and 2015. Loss to follow-up was defined as no clinical and pharmacy contact for at least 90 days after the child missed their last scheduled clinical visit. Non-parametric competing risks models were used to estimate the cumulative incidence of death, LTFU and transfer. Cause-specific Cox regression was used to estimate the hazard ratios of the risk factors of LTFU.

Results

A total of 1039 children aged 0–15 years commenced ART at LCH between 2003 and 2015. Median duration of follow-up was 3.8 years (95% CI: 1.2–6.5), median age at ART initiation was 3.6 years (IQR: 1.3–8.6), 179 (17%) started treatment during their first year of life. At least 167 (16%) were LTFU and we traced 151 (90%). Of those we traced, 39 (26%) had died, 71 (47%) defaulted, 20 (13%) continued ART at other clinics and 21 (14%) continued treatment with gaps. The cumulative incidence of LTFU for the entire cohort was 2.7% (95% CI: 1.9–3.9) at 3 months, 4.1% (95% CI: 2.9–5.4) at 6 months and 14.1% (95% CI: 12.4–16.9) after 5 years on ART. Associated risk factors were: 1) non-disclosure of HIV status at baseline, aHR = 1.9 (1.2–2.9), 2) No phone ownership, aHR = 2.1 (1.6–2.9), 3) starting treatment between 2013 to 2015, aHR = 5.6 (2.2–14.1).

Conclusion

Among the children LTFU mortality and default were substantially high. Children who started treatment in recent years (2013–2015) had the highest hazard of LTFU. Lack of access to a phone and non-disclosure of HIV-status to the index child was associated with higher hazards of LTFU. We recommend re-enforcement of client counselling and focused follow-up strategies using modern technology such as mobile phones as adjunct to current approaches.
Literature
11.
go back to reference Ministry of Health z. Zambian Guidelines for Antiretroviral Therapy of HIV Infection in Infants and Children:Towards Universal Access- Recommendations for a Public Health Approach 2007. 8/27/2017. Ministry of Health z. Zambian Guidelines for Antiretroviral Therapy of HIV Infection in Infants and Children:Towards Universal Access- Recommendations for a Public Health Approach 2007. 8/27/2017.
12.
go back to reference Ministry of Health Z. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2013. 1/25/2018. Ministry of Health Z. Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection. 2013. 1/25/2018.
14.
go back to reference Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017.
17.
go back to reference Joint United Nations Programme on HIV/AIDS U. 90–90-90 An ambitious target to help end the AIDS epidemic. Geneva: UNAIDS; 2014. 5/22/2017 Joint United Nations Programme on HIV/AIDS U. 90–90-90 An ambitious target to help end the AIDS epidemic. Geneva: UNAIDS; 2014. 5/22/2017
19.
go back to reference W.H.O. Use of Antiretroviral Drugs for treating Pregnant Women and Preventing HIV infection in infants. Geneva: W.H.O; 2012. 5/2/2017 W.H.O. Use of Antiretroviral Drugs for treating Pregnant Women and Preventing HIV infection in infants. Geneva: W.H.O; 2012. 5/2/2017
31.
go back to reference Fenner L, Brinkhof MWG, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquired immune Defic Syndr. 2010;54(5):524–32 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925143/pdf/nihms203689.pdf, 8/26/2017.CrossRef Fenner L, Brinkhof MWG, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquired immune Defic Syndr. 2010;54(5):524–32 https://​www.​ncbi.​nlm.​nih.​gov/​pmc/​articles/​PMC2925143/​pdf/​nihms203689.​pdf, 8/26/2017.CrossRef
Metadata
Title
Predictors of loss to follow-up among children on long-term antiretroviral therapy in Zambia (2003–2015)
Authors
Jane N. Mutanga
Simon Mutembo
Amara E. Ezeamama
Xiao Song
Robert C. Fubisha
Kunda Mutesu-Kapembwa
Derrick Sialondwe
Brenda Simuchembu
Jelita Chinyonga
Philip E. Thuma
Christopher C. Whalen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-019-7374-0

Other articles of this Issue 1/2019

BMC Public Health 1/2019 Go to the issue